Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 9;11(12):3306.
doi: 10.3390/jcm11123306.

The Role of Wilms' Tumor Gene (WT1) Expression as a Marker of Minimal Residual Disease in Acute Myeloid Leukemia

Davide Lazzarotto  1 , Anna Candoni  1
Affiliations
Review

The Role of Wilms' Tumor Gene (WT1) Expression as a Marker of Minimal Residual Disease in Acute Myeloid Leukemia

Davide Lazzarotto et al. J Clin Med. .

Abstract

The Minimal Residual Disease(MRD) monitoring in acute myeloid leukemia (AML) is crucial to guide treatment after morphologic complete remission, to define the need for consolidation with allogeneic stem cell transplantation (Allo-SCT), and to detect impending relapse allowing early intervention. However, more than 50% of patients with AML lack a specific or measurable molecular marker to monitor MRD. We reviewed the key studies on WT1 overexpression as a marker of MRD in AML patients undergoing an intensive chemotherapy program, including Allo-SCT. In addition, we provided some practical considerations on how to properly use WT1 expression as an MRD marker, considering its strengths and weaknesses. In order to achieve the best sensitivity and specificity, it is recommended to refer to the standardized method of European LeukemiaNet and its defined threshold (250 WT1 copies/104 Abelson (ABL) on Bone Marrow-BM and 50 WT1 copies/104 ABL on Peripheral Blood-PB), which has been validated in a large and multicenter cohort of patients and normal controls.

Keywords: WT1; acute myeloid leukemia; minimal residual disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The WT1 gene.
See this image and copyright information in PMC

References

    1. Schuurhuis G.J., Heuser M., Freeman S., Béné M.C., Buccisano F., Cloos J., Grimwade D., Haferlach T., Hills R.K., Hourigan C.S., et al. Minimal/measurable residual disease in AML: A consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131:1275–1291. doi: 10.1182/blood-2017-09-801498. - DOI - PMC - PubMed
    1. Heuser M., Freeman S.D., Ossenkoppele G.J., Buccisano F., Hourigan C.S., Ngai L.L., Tettero J.M., Bachas C., Baer C., Béné M.C., et al. 2021 Update on MRD in acute myeloid leukemia: A consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138:2753–2767. doi: 10.1182/blood.2021013626. - DOI - PMC - PubMed
    1. Cilloni D., Gottardi E., De Micheli D., Serra A., Volpe G., Messa F., Rege-Cambrin G., Guerrasio A., Divona M., Lo Coco F., et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia. 2002;16:2115–2121. doi: 10.1038/sj.leu.2402675. - DOI - PubMed
    1. Cilloni D., Renneville A., Hermitte F., Hills R.K., Daly S., Jovanovic J.V., Gottardi E., Fava M., Schnittger S., Weiss T., et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: A European LeukemiaNet study. J. Clin. Oncol. 2009;27:5195–5201. doi: 10.1200/JCO.2009.22.4865. - DOI - PubMed
    1. Yang L., Han Y., Suarez Saiz F., Minden M.D. A tumor suppressor and oncogene: The WT1 story. Leukemia. 2007;21:868–876. doi: 10.1038/sj.leu.2404624. - DOI - PubMed

LinkOut - more resources